Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 3, 2013
Event: Announcement of a global operational realignment plan to improve organizational efficiencies and position the company for growth.
Key Financial Metrics
This filing does not report standard periodic financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial disclosure relates to a specific restructuring event:
- Estimated Restructuring Costs: Approximately $1.5 million (pre-tax basis).
- Cost Composition: Substantially all costs are personnel-related and expected to result in cash expenditures.
- Timing of Expenditures: Substantially all costs are expected to be incurred in the fourth quarter of fiscal 2013.
Material Changes
The material change disclosed is the commitment to a workforce reduction plan:
- Workforce Reduction: Approximately 13 percent of the workforce will be eliminated to address operational redundancies across several locations.
- Completion Timeline: The realignment plan is expected to be completed on or before December 31, 2013.
Outlook, Risks, and Management Commentary
Management Commentary: The realignment is intended to create organizational efficiencies and better position the company for future growth.
Risks and Contingencies: The filing explicitly states that all estimates described regarding the realignment costs may change in the future.
Investor Verification Checklist
- Verify the actual cash outflow for the $1.5 million restructuring charge in the Q4 2013 financial statements.
- Confirm the final number of employees affected by the 13% reduction once the plan is completed by December 31, 2013.
- Monitor future filings for any adjustments to the estimated $1.5 million cost, as the company noted these figures are subject to change.
- Review the full text of the press release (Exhibit 99.1) for specific details on which locations or departments are impacted.